|
|
|
|
Institut Pasteur scientists find way to distinguish between oligomerisation, hydration & shape changes of prot
Research carried out by scientists from the Institut Pasteur in Paris, France, has shown that size exclusion chromatography followed by triple detection array (SEC-TDA) can distinguish between oligomerisation, hydration and shape changes of...
|
|
|
Shamrock Structures Awarded Phase I Small Business Innovation Research Grant To Develop Wide Angle X-ray Scatt
Shamrock Structures, LLC, a privately held structural biology company, announced today that it was awarded a Phase I Small Business Innovation Research (SBIR) grant to develop Wide Angle X-ray Scattering (WAXS) for Drug Discovery.
|
|
|
Researchers characterize hydrodynamic changes in polypeptides
Research carried out by scientists from the Institut Pasteur in Paris, France, has shown that size exclusion chromatography followed by triple detection array (SEC-TDA) can distinguish between oligomerization, hydration and shape changes of...
|
|
|
Shamrock Structures Awarded Phase I Small Business Innovation Research Grant To Develop Wide Angle X-ray Scatt
The process of lead drug discovery presents an early and significant bottleneck in the process of pharmaceutical drug design and slows the ultimate development of new therapeutic treatments.The goal of this project is to develop the use...
|
|
|
Institut Pasteur Researchers Use Malvern Instruments' Triple Detection Chromatography System To Characterise H
: Malvern, UK: Research carried out by scientists* from the Institut Pasteur in Paris, France, has shown that size exclusion chromatography followed by triple detection array (SEC-TDA) can distinguish between oligomerisation, hydration and...
|
|
|
Shamrock Structures Awarded Phase I Small Business Innovation Research Grant To Develop Wide Angle X-ray Scatt
- Shamrock Structures, LLC, a privately held structural biology company, announced today that it was awarded a Phase I Small Business Innovation Research (SBIR) grant to develop Wide Angle X-ray Scattering (WAXS) for Drug Discovery.
|
|
|
Shamrock Structures Awarded Phase I Small Business Innovation Research Grant To Develop Wide Angle X-ray Scatt
Shamrock Structures, LLC, a privately held structural biology company, announced today that it was awarded a Phase I Small Business Innovation Research (SBIR) grant to develop Wide Angle X-ray Scattering (WAXS) for Drug Discovery.
|
|
|
Osteoporosis Risk Factors: Reports from Akita University advance knowledge in osteoporosis risk factors
Reports from Akita University advance knowledge in osteoporosis risk factors A new study, 'Impact of spinal kyphosis on gastroesophageal reflux disease symptoms in patients with osteoporosis,' is now available.'Spinal kyphosis has been...
|
|
|
The Effect of the Angle of Suture Anchor Insertion on Fixation Failure at the Tendon-Suture Interface After Ro
_ The Effect of the Angle of Suture Anchor Insertion on Fixation Failure at the Tendon-Suture Interface After Ro.
|
|
|
Advanced Orthodontic Education As Seen by the Prospective Resident
(Click the title below to leave the MDLinx Network and go to the Journal's Website) Angle Orthodontist , 06/19/09 Print Save in My Library Free Full Text Isaacson RJ - This situation was not brought on by orthodontists.Schools have...
|
|
|
Primary Open-Angle Glaucoma
_ Primary Open-Angle Glaucoma.
|
|
|
Skin cancer screening clinic June 9
Posted by Sudbury Northern Life Greater Sudbury dermatologist Lyne Giroux checks Angle Mrochek for skin cancer with an ultra violet camera.Giroux is holding a free skin cancer screening on Tuesday, June 9 from 5 p.m. to 8 p.m.
|
|
|
Mary Anderson to be Honored as HBA Rising Star
PARSIPPANY, N.J., May 7 Mary Anderson, president of HLS, will be honored as an industry Rising Star by the Healthcare Businesswomens Association (HBA) at its 20th Woman of the Year award luncheon being held today at the Hilton New York.
|
|
|
Inotek Pharmaceuticals Presents Preclinical Data in Support of Novel Glaucoma Candidate, INO-8875 at ARVO
Today's results directly support our ongoing Phase 1/2 clinical study of INO-8875 in glaucoma and more broadly validate Inotek's growing ophthalmology pipeline which is focused on the development of therapeutics with novel mechanisms...
|
|
|
Inotek Pharmaceuticals' Novel Glaucoma Candidate, INO-8875, Selected for Presentation at the ARVO 2009 Annual
LEXINGTON, Mass.--(BUSINESS WIRE)--Inotek Pharmaceuticals today announced that preclinical data supporting the Companys lead clinical-stage drug candidate in glaucoma, INO-8875, will be presented in a poster session at the Association...
|
